![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Study of ABT-267 2-Day Monotherapy Followed By 12-Week Combination Therapy In Treatment-Naïve Patients With Chronic HCV Genotype 1 Infection
|
|
|
Reported by jules Levin
EASL 2013 April 25-28 Amsterdam
Michael Epstein1, Franco Felizarta2, Thomas Marbury3, Prajakta Badri4, Victoria Mullally4, Tami Pilot-Mati as4, Carolyn M Setze4, Andrew L Campbell4, Barry Bernstein4
1Investi gati ve Clinical Research, Annapolis, Maryland, United States; 2Private Practi ce, Bakersfi eld, California, United States; 3Orlando Clinical Research Center, Orlando, Florida, United States; 4AbbVie Inc., North Chicago, Illinois, United States
![EASL1.gif](../images/042913/042913-6/EASL1.gif)
![EASL2.gif](../images/042913/042913-6/EASL2.gif)
![EASL3.gif](../images/042913/042913-6/EASL3.gif)
![EASL4.gif](../images/042913/042913-6/EASL4.gif)
![EASL5.gif](../images/042913/042913-6/EASL5.gif)
![EASL6.gif](../images/042913/042913-6/EASL6.gif)
![EASL7.gif](../images/042913/042913-6/EASL7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|